Andrology Unit, Department of Urology, Pontificia Universidad Católica de Chile, Santiago.
Department of Urology, Clínica Las Condes, Santiago.
Arch Ital Urol Androl. 2022 Mar 29;94(1):65-69. doi: 10.4081/aiua.2022.1.65.
Evidence regarding demand trends for erectile dysfunction (ED) treatments are scarce in South America. This study aims to evaluate trends in ED treatments in Chile over a 10-year period (2010- 2020) and estimate the potential number of candidates for penile prosthesis.
Sales trends of pharmacological treatments and penile prosthesis were obtained from market studies. The potential number of candidates for penile prosthesis implantation was calculated by crossing epidemiological data with previously reported ED prevalence, proportion of sexually active men, percentage of men seeking medical assistance for ED, and the proportion of patients who are non-responders to ED oral drug therapies Results: In the 10-year studied period, the Chilean male population older than 50 years increased 34.7%, with an average annual variation (AAV) of 3.4%. For the same period, the sales of oral drug therapies for ED increased by 71.3% (AAV 6.2%), the sales of intracavernosal vasoactive agents (ICVA) decreased by 0.4% (AAV -0.2%), and penile prosthesis sales increased by 113% (AAV 6.7%). We estimated that only 0.05% of sexually active men older than 50 years old with ED who sought medical assistance finally had a penile prosthesis implanted to manage their condition.
Demand for ED oral drug therapies significantly increased in Chile during the last decade, while ICVA remained stable. The annual rate of penile prosthesis implantation increased. However, the gap between the potential penile prosthesis candidates and the actual number of devices implanted is suspected to remain extremely high.
南美洲关于勃起功能障碍（ED）治疗需求趋势的证据很少。本研究旨在评估智利在 10 年内（2010-2020 年）ED 治疗趋势，并估计阴茎假体植入的潜在候选人数。
从市场研究中获得了药物治疗和阴茎假体的销售趋势。通过将流行病学数据与先前报告的 ED 患病率、活跃男性比例、寻求医疗帮助治疗 ED 的男性比例以及 ED 口服药物治疗无反应者的比例交叉，计算了阴茎假体植入的潜在候选人数。
在所研究的 10 年内，50 岁以上的智利男性人口增加了 34.7%，平均年增长率（AAV）为 3.4%。同期，ED 口服药物治疗的销售额增长了 71.3%（AAV 为 6.2%），腔内血管活性药物（ICVA）的销售额下降了 0.4%（AAV 为-0.2%），而阴茎假体的销售额增长了 113%（AAV 为 6.7%）。我们估计，只有 0.05%的 50 岁以上、寻求医疗帮助治疗 ED 的活跃男性最终接受阴茎假体植入来治疗他们的病情。
在过去十年中，智利对 ED 口服药物治疗的需求显著增加，而 ICVA 保持稳定。阴茎假体植入的年增长率增加。然而，潜在的阴茎假体候选人和实际植入设备数量之间的差距可能仍然极高。
